National Cancer Institute U.S. National Institutes of Health | www.cancer.gov
SPORES Logo - Translational Research, Clinical, Pre-Clinical, Basic, Pre-Clinical SPOREs - Specialized Programs of Research Excellence
Home Organization of the OSB Current SPORE Programs Information for the Public PART Program Information for Applicants IntraSPORE Communications  

Organization of the Organ Systems Branch
Overview, organization, staff listing and contact information

Current SPORE Programs
Abstracts and Cores of currently funded SPOREs

Information for the Public
Information for the public interested in activities of the SPORE program and frequently asked questions

PART Program
Information about the Patient Advocate Research Team Program

Information for Applicants
Information for researchers interested in applying for the SPORE program

IntraSPORE Communications
(access restricted to SPORE Investigators)



[ SPOREs: Brain | Breast | GI | GU | GYN | Head and Neck | Leukemia | Lung | Lymphoma | Myeloma | Ovarian | Pancreatic | Prostate | Skin ]

Ovarian SPOREs

Ovarian cancer is the second most common gynecological cancer in women, but ranks first (above cervical cancer) in cancer deaths. Approximately 23,100 new ovarian cancers were diagnosed in the United States in the year 2000 and about 14,000 women died from this disease. The high mortality rate stems from an overall lack of early symptoms or screening methods for the disease. As a result, most ovarian cancer patients are diagnosed with advanced stage disease. Women with a family history of either breast, ovarian, or non-polyposis colon cancer are at an increased risk for developing ovarian cancer. The Ovarian Cancer SPORE program was initiated in 1999 with the funding of four sites. The relatively low incidence of this disease (as compared to other cancers, such as breast cancer), as well as the team concept of the SPORE program, has encouraged a number of Inter-SPORE collaborations aimed at developing much needed prognostic, screening, prevention, and therapeutic tools for ovarian cancer. Additional solicitations for Ovarian Cancer SPOREs are planned in the years 2003, 2004, and 2005.

To view the associated abstract, click on the name/address below.

Robert C. Bast, Jr., M.D.
University of Texas, MD Anderson Cancer Center
1515 Holcombe Blvd., Box 355
Houston, TX 77030
Tel: (713) 792-7770
Fax: (713) 794-1807

Robert F. Ozols, M.D., Ph.D.
Fox Chase Cancer Center
7701 Burholme Avenue
Philadelphia, PA 19111
Tel: (215) 728-2673
Fax: (215) 728-5346

Edward E. Partridge, M.D.
University of Alabama at Birmingham
618 South 20th Street
538 Old Hillman Bldg., Rm. 538
Birmingham, AL 35233-7333
Tel: (205) 934-4986
Fax: (205) 975-6174

Nicole Urban, Sc.D.
Fred Hutchinson Cancer Research Center
Cancer Prevention Research Program
1100 Fairview Ave., North
Box 19204
MP900
Seattle, WA 98109-1024
Tel: (206) 667-4677
Fax: (206) 667-7850

Daniel Cramer, M.D., Sc.D.
Brigham and Women's Hospital
Ob/Gyn Epidemiology Center
221 Longwood Ave.
Boston, MA 01225
Tel: (617) 732-4895
Fax: (617)732-4899

 



   Clinical Trials

   Avon-NCI Progress for Patients Program Clinical Trials Conducted by Ovarian SPOREs

   Avon-NCI Progress for Patients Program Clinical Trials Conducted by Breast SPOREs

National Cancer Institute Department of Health and Human Services National Institutes of Health FirstGov.gov